Development of bio-marine products.

  New CEO and BoD chair  Jul 5 21

  Gen. Assembly Jun 15 21

  Dagens Medisin   Mar 26 21

  Subs. rights   Mar 31 21

 EU Invest  Mar 10 21

 

 

 

 

 

Regenics AS is a private Norwegian biotechnology company based in Oslo. We develop, licence and distribute our marine wound devices using therapeutically active bioctives from unfertilized salmon roe. Final development of devices for US/EU registration is scheduled for 2023-2024.

Wound Healing - Skin diseases

Regenics is developing several products for therapeutic skin applications. The most advanced is COLLEX®, a 3D-bioprinted wound patch and VERNEX® spray for wound healing. 

Vernex® - medical device for wound healing

Regenics develops medical devices for US, EU and Asian markets. Regenics bioactives purified from salmon roe have pluripotent stem cell resembling effects that incresee the rate of wound helaing. Collex® is a 3D-bioprinted first in class wound patch. Vernex® is a wound spray for larger wounds. WoundClear® is an enzyme under development for wound debridement.

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.